A research team from the INMA Project (Childhood and Environment) has analyzed how pet ownership during early childhood may ...

Spanish is the second most spoken language in the United States. Many students on campus have grown up with the language or ...

MAIA Biotechnology, Inc. ((MAIA)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...

Over 52 weeks, treprostinil was superior to placebo in absolute FVC by 95.6 mL from baseline, regardless of background therapy, smoking status, or supplemental oxygen use. United Therapeutics ...

MENLO PARK, Calif., June 18, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced positive top-line ...

“Study Group” is gearing up for a second season! Premiered this past January and based on the popular webtoon of the same name, “Study Group” is a high school action-comedy about Youn Ga Min (Hwang ...

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today noted that Akeso, Inc. (Akeso, HKEX Code: 9926.HK) announced that ivonescimab was approved by ...

Alzheimer’s disease (AD) is a severe neurodegenerative disorder with a growing global burden. With the rising incidence of AD, the need for novel therapeutic targets has become increasingly critical.

EMBED <iframe src="https://archive.org/embed/spanish-airports-2" width="560" height="384" frameborder="0" webkitallowfullscreen="true" mozallowfullscreen="true ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe ...

NEW YORK – Within I-SPY 2.2, an adaptive, biomarker-stratified basket trial, researchers have identified promising neoadjuvant treatment strategies for breast cancer patients based on complex ...

Long-term survival outcomes for hormonal therapy in premenopausal patients with clinical stage I endometrial cancer. Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus ...